TrialRheumatology (Oxford, England)2025

Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study.

Lorinda Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.